Ultragenyx Q2 2023 revenue $108.3M (+21% YoY); reaffirms 2023 guidance

Ultragenyx Pharmaceutical Inc.

2023-Q2 EPS reported -$4.58 revenue$208,805,000

Q2 total revenue $108.3M vs $89.3M YoY; Crysvita $83.0M (+20%), Dojolvi $16.5M, Mepsevii $8.4M.
Net loss $159.8M ($2.25/sh) compared to $158.2M ($2.26) in Q2 2022; cash and equivalents $618.4M.
Reaffirmed FY2023 guidance: total revenue $425-450M, Crysvita $325-340M, Dojolvi $65-75M.
Setrusumab Phase 2 OI data: 9.4% BMD increase at 20mg/kg in 3 months; Phase 3 Orbit/Cosmic enrolling.
Howard Horn appointed CFO and EVP Corporate Strategy effective Oct 16, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ultragenyx Pharmaceutical Inc. reported the quarter ended June 30, 2023 results: revenue $108.3 million, net income net loss of $159.8 million, or $2.25 per share basic and diluted, EPS $2.25 per share basic and diluted. Guidance reaffirmed.

Period: the quarter ended June 30, 2023
Revenue: $108.3 million
Net income: net loss of $159.8 million, or $2.25 per share basic and diluted
EPS: $2.25 per share basic and diluted
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Mepsevii 8,439 4,933 16,919 9,794 Evkeeza 365 — 577 — Daiichi Sankyo — 1,479 1,479 4,728 Total revenues $ 108,309 $ 89,343 $ 208,805 $ 169,278 Total Revenues Ultragenyx reported $108.3 million in total revenue for the second quarter of 2023, which represents 21% growth compared to the second quarter 2022. This includes second quarter 2023 Crysvita revenue in North

View on SEC.gov

Browse all earnings releases →

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-037962

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.